Methods for Identifying Candidate Therapeutics for Systemic Lupus Erythematosus Using Single-Cell RNA Sequencing of Peripheral Blood Mononuclear Cells and Transcriptomic Reversal Scoring — Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in systemic lupus erythematosus (SLE) using single-cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from 2 new-onset SLE patients and 1 healthy control, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (SLE vs HC primary, plus B cell, T cell, monocyte, ISG-high, and pro-SLE cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE162577 (10,756 cells after quality filtering) identified 417 NOVEL_ALL priority candidates — the highest NOVEL_ALL rate (77%) across the inventor's series of scRNA-seq drug repurposing analyses. Top candidates: Dichlorodiamine-Platinum (priority 202,502), MRE-269 (prostacyclin agonist, 159,481), Crenolanib (FLT3/PDGFR inhibitor, 127,564), EPZ-5676 (DOT1L inhibitor, 110,960), Nilutamide (AR antagonist, 113,195), KPT-330/selinexor (XPO1 inhibitor, 24,415). Crenolanib implicates plasmacytoid DC FLT3 signaling as a novel SLE therapeutic target; EPZ-5676 implicates H3K79 methylation in ISG regulation; KPT-330 achieves NOVEL_ALL status for the fourth consecutive pipeline. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Computational Drug Discovery Methods Single-cell and spatial transcriptomics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
21 March 2026
Language
EN